XERIS PHARMACEUTICALS INC short interest in 2020
In 2020, XERIS PHARMACEUTICALS INC's disclosed short interest ran from 8.09% of shares outstanding on 15 Jan 2020 to 10.37% on 31 Dec 2020, a change of +2.28 percentage points. The year's high was 38.20% on 15 Oct 2020 and its low 3.70% on 15 Jun 2020, averaging 16.79% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.88 days on 31 Jan 2020. Full history: XERIS PHARMACEUTICALS INC.
Cite this page
2020 in figures
- Start of year
- 8.09% (15 Jan 2020)
- End of year
- 10.37% (31 Dec 2020)
- Change
- +2.28 pp
- High
- 38.20% (15 Oct 2020)
- Low
- 3.70% (15 Jun 2020)
- Average
- 16.79%
- Highest days to cover
- 12.88 (31 Jan 2020)
- SEC filings marked
- 9
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2020 | 8.09% | 5.45 | |
| 31 Jan 2020 | 7.90% | 12.88 | |
| 14 Feb 2020 | 4.71% | 1.25 | results (8-K) |
| 28 Feb 2020 | 5.61% | 2.22 | |
| 13 Mar 2020 | 5.86% | 2.60 | results (8-K), 10-K filed |
| 31 Mar 2020 | 6.39% | 4.20 | |
| 15 Apr 2020 | 6.74% | 5.18 | |
| 30 Apr 2020 | 5.65% | 3.81 | |
| 15 May 2020 | 6.23% | 2.36 | 10-Q filed, results (8-K) |
| 29 May 2020 | 3.72% | 2.32 | |
| 15 Jun 2020 | 3.70% | 3.69 | |
| 31 Jul 2020 | 28.70% | 5.98 | |
| 14 Aug 2020 | 32.90% | 3.68 | 10-Q filed, results (8-K) |
| 31 Aug 2020 | 35.91% | 3.50 | |
| 15 Sep 2020 | 34.59% | 5.43 | |
| 30 Sep 2020 | 37.87% | 5.47 | |
| 15 Oct 2020 | 38.20% | 10.98 | |
| 30 Oct 2020 | 31.33% | 12.02 | |
| 13 Nov 2020 | 30.23% | 11.27 | 10-Q filed, results (8-K) |
| 30 Nov 2020 | 13.97% | 4.36 | |
| 15 Dec 2020 | 10.77% | 2.96 | |
| 31 Dec 2020 | 10.37% | 2.96 |
See also: XERIS PHARMACEUTICALS INC's full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.